We measured the protein stability of cMyc in PRMT5-silenced pancreatic cancer cells after treatment with the protein synthesis inhibitor cycloheximide (CHX) at 100 μM, which could allow the protein stability of cMyc to be assessed. The gene discussed is PRMT5; the disease is pancreatic neoplasm.